Response and Shanghai Elite expand Chinese distribution deal for RAMP cardiovascular products

8 February 2015 (Last Updated November 22nd, 2018 11:18)

Canada-based Response Biomedical has expanded the scope of its agreement with China-based Shanghai Elite Biotech to distribute its cardiovascular portfolio of RAMP products.

Canada-based Response Biomedical has expanded the scope of its agreement with China-based Shanghai Elite Biotech to distribute its cardiovascular portfolio of RAMP products.

The RAMP platform includes a reader and single-use disposable test cartridges, and holds the potential to be adapted to any other medical and non-medical immunoassay based test currently performed in laboratories.

As part of the deal that is effective from 23 April, Shanghai Elite will become the exclusive national distributor in China for Response's RAMP branded cardiovascular point of care testing (POCT) portfolio.

Response interim CEO Dr Anthony Holler said: "Response and Shanghai Elite initially entered into a distribution agreement for certain provinces in eastern and southern China in the fourth quarter of 2013.

"The RAMP platform includes a reader and single-use disposable test cartridges, and holds the potential to be adapted to any other medical and non-medical immunoassay based test currently performed in laboratories."

"We are confident in Shanghai Elite's ability to grow sales in their existing territory as well as the expanded territory in China for which they will take over responsibility for from our previous distributor effective April 23, 2015."

The deal will see Shanghai Elite own exclusive distribution rights for Response's RAMP branded cardiovascular POCT portfolio in China excluding Taiwan, Hong Kong and Macao Special Administrative Region.

In addition, product pricing levels and exclusive sales territories are contingent upon the achievement of certain sales minimums, and Response committed to offer certain amounts of marketing support to Shanghai Elite.

Response chief operating officer Dr Barbara Kinnaird said: "Response owns our own regulatory clearances in China and has an established regional office in Shanghai, which allows us to decisively and effectively manage our China distribution channels, thereby enabling us to better ensure that our distributors are satisfactorily meeting both their contractual sales commitments, and our growth expectations."

Response is focused on developing, manufacturing and marketing rapid on-site diagnostic tests for use with its RAMP platform for clinical, biodefense and environmental applications.